Abstract
BackgroundImmunogenicity influences adalimumab levels and therefore clinical response in patients with rheumatic diseases.ObjectivesTo study the relation between clinical response, adalimumab levels and anti-drug antibodies (ADA) in ankylosing spondylitis (AS) patients.MethodsObservational...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have